25263-44-9

Basic information

• Product Name: M-HYDROXY BENZYL CYANIDE
• Synonyms: 3-HYDROXYPHENYLACETONITRILE;M-HYDROXYPHENYLACETONITRILE;M-HYDROXY BENZYL CYANIDE;M-HYDROXY BENZYL CYANIDE(3-HYDROXYPHENYL)-ACETONITRILE;2-(3-hydroxyphenyl)acetonitrile;3-Hydroxy-Benzeneacetonitrile
• CAS NO: 25263-44-9
• Molecular Formula: C₈H₇NO
• Molecular Weight: 133.15
• Product Categories: Aromatic Nitriles
• Mol File: 25263-44-9.mol

Chemical Properties

• Melting Point: 53 °C
• Boiling Point: 305.5°C at 760 mmHg
• Flash Point: 138.6 °C
• Appearance: /
• Density: 1.167 g/cm³
• Vapor Pressure: 0.000452mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.51±0.10(Predicted)
• CAS DataBase Reference: M-HYDROXY BENZYL CYANIDE(CAS DataBase Reference)
• NIST Chemistry Reference: M-HYDROXY BENZYL CYANIDE(25263-44-9)
• EPA Substance Registry System: M-HYDROXY BENZYL CYANIDE(25263-44-9)

Safety Data

• Hazardous Substances Data: 25263-44-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7NO/c9-5-4-7-2-1-3-8(10)6-7/h1-3,6,10H,4H2

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 140-29-4 phenylacetonitrile 
• 621-50-1 (3-nitrophenyl)acetonitrile 
• 49617-80-3 m-(bromomethyl)phenyl acetate 
• 122-46-3 3-acetoxytoluene 
• 4623-24-9 2-(3-aminophenyl)acetonitrile 

Downstream Products

• 621-37-4 m-hydroxyphenylacetic acid 
• 123724-18-5 2-<<3-(cyanomethyl)phenoxy>methyl>quinoline 
• 20967-96-8 2-(3-benzyloxyphenyl)acetonitrile 
• 139368-06-2 4-(3-hydroxyphenyl)-4-(ethoxycarbonyl)-3,4,5,6-tetrahydro-2H-pyran 
• 120028-55-9 3-(2-quinazolinylmethoxy)benzenacetonitrile 
• 259538-74-4 tert-Butyl (2 R)-2-{[3-(cyanomethyl)phenoxy]methyl}-1-pyrrolidinecarboxylate 
• 1193434-40-0 5-(3-(2,6-dimethylbenzyloxy)benzyl)-1H-tetrazole 
• 1307837-71-3 C₁₁H₁₂O₃ 

Relevant articles and documents

TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including g

FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES

Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification and pharmaceutica

FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES

Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R1, R2, R2', R3, R4, R5 and R6 have the meanings as defined in the specification a

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

The present invention provides a Compound of formula (I), wherein: R1 is a group selected from -CH2OH,-NH(CO)H; and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH-, wherei

Novel azo dye compound

A compound represented by formula (I): Formula (I) wherein Z1 and Z2 each are atoms necessary for forming an aromatic ring; V1 and V2 each are a substituent W1 or W2; when at least one V1 is W1, at least one V2 is W2, or when at least one V1 is W2, at least one V2 is W1; r is 1 to 4; s is 1 to 4; M1 is a counter ion; m1 is the number necessary for neutralizing charge; W1 is a hydroxyl, primary- or secondary- or tertiary-amino, acylamino, or sulfonamido group; W2 is a nitro, cyano, alkoxycarbonyl, aryloxycarbonyl, alkyl- or aryl-sulfonyl, carbamoyl, sulfamoyl, alkenyl, alkynyl, aryl, heterocyclic, sulfo, carboxyl, heterocyclic oxy, ammonio, alkyl- or aryl-sulfinyl, alkyl- or aryl-sulfonyl, acyl, or aryl- or heterocyclic-azo group; and the aromatic ring may have a substituent other than V1 and V2.

ANTITHROMBOTIC AGENTS

Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisa

Antithrombotic agents

Compounds of formula (I) : are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilis

PYRAN DERIVATIVES AND THEIR USE AS INHIBITORS OF 5-LIPOXYGENASE

The invention concerns a cyclic ether derivative of the formula I, wherein Ar1 is optionally substituted phenyl, naphthyl or a 9-or 10-membered bicyclic heterocyclic moiety; A1 is a direct link to X1 or (l-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphony

Synthesis of Peptide Alkaloids. 5. New Method for Synthesis of Ansa Peptides. Amino Acids and Peptides. 34

Fourteen-membered para-ansa compounds and 13-membered meta-ansa compounds have been synthesized by catalytic hydrogenation of the pentafluorophenyl esters of ω-(Z)-amino carboxylic acids in 50percent and 80percent yields, respectively.